There is no official maximum duration for Prolia. The FDA has not set a time limit on treatment, and many patients stay on it for 10 years or longer. The more important question, and the reason this gets complicated, is that stopping Prolia carries real risks, which means the decision about how long to take it requires careful planning.
Prolia is given as an injection once every six months. Unlike some osteoporosis medications where doctors recommend periodic breaks, Prolia doesn’t work that way. Its effects wear off quickly once you stop, and that rapid reversal can cause serious problems.
What the Long-Term Data Shows
The longest clinical trial of Prolia followed postmenopausal women for 10 years. Over that period, bone density continued to climb without plateauing. Women who took Prolia for the full decade gained an average of 21.7% bone density at the lumbar spine, 9.2% at the total hip, and 9.0% at the femoral neck. Those are substantial gains, and they kept accumulating year after year.
Fracture rates also stayed consistently low throughout. The yearly incidence of new spinal fractures ranged from 0.90% to 1.86% during the extension study, similar to what was seen in the first three years and well below what would be expected without treatment. There was no sign that the drug became less effective over time, which is part of why there’s no upper limit on its use.
Why Stopping Prolia Is Risky
Prolia works by blocking a protein that activates bone-removing cells. When you stop the drug, those cells come roaring back. Bone density can drop rapidly, sometimes falling below where it was before treatment started. This rebound effect is the central challenge of Prolia therapy.
The most concerning consequence is a spike in spinal fractures. The UK’s drug safety agency has documented cases of multiple vertebral fractures occurring within 18 months of stopping or even delaying Prolia injections, with some happening in the first nine months. These aren’t single fractures. Patients have experienced several vertebral fractures in quick succession, a pattern rarely seen with other osteoporosis drugs.
This rebound risk exists whether you’ve been on Prolia for two years or ten. It means you can’t simply decide to stop taking it without a transition plan.
The Goal-Directed Approach
Current guidelines from the American Society for Bone and Mineral Research recommend a goal-directed strategy rather than a fixed treatment duration. Instead of prescribing Prolia for a set number of years, your doctor sets a bone density target based on your fracture risk. Treatment continues until you reach that target, then shifts to a maintenance phase.
Once you’ve hit your target, the options include continuing Prolia, switching to a different medication, or transitioning off Prolia with a protective medication in place. What’s not recommended is simply stopping without a plan. The 2024 ASBMR position statement specifically warns that the benefits of treatment wane if medication is discontinued, and that bone density drops rapidly after stopping most agents, with Prolia posing the additional risk of multiple vertebral fractures.
For patients who haven’t yet reached their bone density goals, the recommendation is to continue the most effective treatment for at least another two years before reassessing.
Transitioning Off Prolia Safely
If you and your doctor decide it’s time to stop Prolia, the standard approach is to start a bisphosphonate (a different class of osteoporosis drug that binds to bone and provides longer-lasting protection). The timing matters. Bisphosphonates need to attach to actively remodeling bone to work, so giving them too early, while Prolia is still fully suppressing bone turnover, may reduce their effectiveness.
Research suggests that an intravenous bisphosphonate given around six to nine months after the last Prolia dose, or when blood markers show bone turnover is picking back up, may offer the best protection. Some patients need more than one dose to fully prevent bone loss. For those who can’t tolerate bisphosphonates, an oral version can serve as a bridge until another option becomes available.
The transition after short-term Prolia use (under three years) appears more straightforward. After long-term use, the most effective transition regimen is less certain, and your doctor may monitor bone turnover markers through blood tests to guide the timing.
Rare Side Effects With Extended Use
Two rare complications get more attention the longer you take Prolia: jawbone damage (osteonecrosis of the jaw) and unusual thigh bone fractures (atypical femoral fractures). Both are linked to prolonged suppression of bone remodeling.
Jawbone complications are uncommon in osteoporosis patients on Prolia. In the 10-year clinical trial, the risk was approximately 0.05%. However, a real-world study of patients undergoing tooth extractions while on Prolia found a higher rate of 2.3%. The difference likely reflects that dental procedures, particularly extractions, are the main trigger. If you’re on long-term Prolia and need dental surgery, this is worth discussing with both your dentist and your prescribing doctor beforehand.
Atypical femoral fractures are also rare but have been reported with extended use. These are stress fractures in the thigh bone that can occur with minimal trauma. Persistent or new thigh or groin pain while on Prolia warrants imaging to rule this out.
How Treatment Length Is Decided in Practice
For most patients, the practical answer is that Prolia is a long-term commitment. Many people stay on it for five to ten years or more, particularly if they started with severe osteoporosis or have a high fracture risk. The drug keeps working as long as you keep taking it, and the consequences of stopping abruptly are serious enough that doctors are cautious about discontinuation.
Your doctor will typically monitor your bone density with periodic scans and may check blood markers of bone turnover to assess how well the drug is working. The decision to continue, switch, or stop is based on whether you’ve reached a bone density target that meaningfully lowers your fracture risk, whether you’re experiencing side effects, and whether a safe transition plan is feasible. If you’re tolerating Prolia well and your bone density is still improving, there’s no biological reason you can’t continue indefinitely.